The use of medications approved for Alzheimer's disease in autism spectrum disorder: A systematic review

Frontiers in Pediatrics

Volumn 2, Issue AUG, 2014, Pages

  Rossignol, Daniel A ^a   Frye, Richard E ^b  

^a Rossignol Medical Center   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Autism; Medications; NMDA antagonist

Indexed keywords

EID: 84925086437     PISSN: None     EISSN: 22962360     Source Type: Journal    
DOI: 10.3389/fped.2014.00087     Document Type: Review

References (73)

1. Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators; Centers for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorder among children aged 8 years-autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ (2014) 63(Suppl 2):1-21
2. Scott LJ, Dhillon S. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs (2007) 9(5):343-54. doi:10.2165/00148581-200709050-00006
3. Ghanizadeh A, Sahraeizadeh A, Berk M. A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry Hum Dev (2014) 45(2):185-92. doi:10.1007/s10578-013-0390-x
4. Frye RE, Rossignol D, Casanova MF, Brown GL, Martin V, Edelson S, et al. A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel. Front Public Health (2013) 1:31. doi:10.3389/fpubh.2013.00031
5. Rossignol DA. Novel and emerging treatments for autism spectrum disorders: a systematic review. Ann Clin Psychiatry (2009) 21(4):213-36
6. Sokol DK, Maloney B, Long JM, Ray B, Lahiri DK. Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links. Neurology (2011) 76(15):1344-52. doi:10.1212/WNL.0b013e3182166dc7
7. Woodruff-Pak DS, Vogel RW III, Wenk GL. Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A (2001) 98(4):2089-94. doi:10.1073/pnas.98.4.2089
8. Deutsch SI, Urbano MR, Neumann SA, Burket JA, Katz E. Cholinergic abnormalities in autism: is there a rationale for selective nicotinic agonist interventions? Clin Neuropharmacol (2010) 33(3):114-20. doi:10.1097/WNF.0b013e3181d6f7ad
9. Perry EK, Lee ML, Martin-Ruiz CM, Court JA, Volsen SG, Merrit J, et al. Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry (2001) 158(7):1058-66. doi:10.1176/appi.ajp.158.7.1058
10. Ray MA, Graham AJ, Lee M, Perry RH, Court JA, Perry EK. Neuronal nicotinic acetylcholine receptor subunits in autism: an immunohistochemical investigation in the thalamus. Neurobiol Dis (2005) 19(3):366-77. doi:10.1016/j.nbd.2005.01.017
11. Lee M, Martin-Ruiz C, Graham A, Court J, Jaros E, Perry R, et al. Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain (2002) 125(Pt 7):1483-95. doi:10.1093/brain/awf160
12. Blatt GJ, Fitzgerald CM, Guptill JT, Booker AB, Kemper TL, Bauman ML. Density and distribution of hippocampal neurotransmitter receptors in autism: an autoradiographic study. J Autism Dev Disord (2001) 31(6):537-43. doi:10.1023/A:1013238809666
13. Suzuki K, Sugihara G, Ouchi Y, Nakamura K, Tsujii M, Futatsubashi M, et al. Reduced acetylcholinesterase activity in the fusiform gyrus in adults with autism spectrum disorders. Arch Gen Psychiatry (2011) 68(3):306-13. doi:10.1001/archgenpsychiatry.2011.4
14. Lee TL, Raygada MJ, Rennert OM. Integrative gene network analysis provides novel regulatory relationships, genetic contributions and susceptible targets in autism spectrum disorders. Gene (2012) 496(2):88-96. doi:10.1016/j.gene.2012.01.020
15. Yasui DH, Scoles HA, Horike S, Meguro-Horike M, Dunaway KW, Schroeder DI, et al. 15q11.2-13.3 chromatin analysis reveals epigenetic regulation of CHRNA7 with deficiencies in Rett and autism brain. Hum Mol Genet (2011) 20(22):4311-23. doi:10.1093/hmg/ddr357
16. McTighe SM, Neal SJ, Lin Q, Hughes ZA, Smith DG. The BTBR mouse model of autism spectrum disorders has learning and attentional impairments and alterations in acetylcholine and kynurenic acid in prefrontal cortex. PLoS One (2013) 8(4):e62189. doi:10.1371/journal.pone.0062189
17. Karvat G, Kimchi T. Acetylcholine elevation relieves cognitive rigidity and social deficiency in a mouse model of autism. Neuropsychopharmacology (2014) 39(4):831-40. doi:10.1038/npp.2013.274
18. Ghaleiha A, Ghyasvand M, Mohammadi MR, Farokhnia M, Yadegari N, Tabrizi M, et al. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: a randomized, double-blind, placebo-controlled trial. J Psychopharmacol (2014) 28(7):677-85. doi:10.1177/0269881113508830
19. Brown MS, Singel D, Hepburn S, Rojas DC. Increased glutamate concentration in the auditory cortex of persons with autism and first-degree relatives: a (1)H-MRS study. Autism Res (2013) 6(1):1-10. doi:10.1002/aur.1260
20. Bejjani A, O'Neill J, Kim JA, Frew AJ, Yee VW, Ly R, et al. Elevated glutamatergic compounds in pregenual anterior cingulate in pediatric autism spectrum disorder demonstrated by 1H MRS and 1H MRSI. PLoS One (2012) 7(7):e38786. doi:10.1371/journal.pone.0038786
21. Bernardi S, Anagnostou E, Shen J, Kolevzon A, Buxbaum JD, Hollander E, et al. In vivo 1H-magnetic resonance spectroscopy study of the attentional networks in autism. Brain Res (2011) 1380:198-205. doi:10.1016/j.brainres.2010.12.057
22. Horder J, Lavender T, Mendez MA, O'Gorman R, Daly E, Craig MC, et al. Reduced subcortical glutamate/glutamine in adults with autism spectrum disorders: a [(1)H]MRS study. Transl Psychiatry (2013) 3:e279. doi:10.1038/tp.2013.53
23. Page LA, Daly E, Schmitz N, Simmons A, Toal F, Deeley Q, et al. In vivo 1H-magnetic resonance spectroscopy study of amygdala-hippocampal and parietal regions in autism. Am J Psychiatry (2006) 163(12):2189-92. doi:10.1176/appi.ajp.163.12.2189
24. Doyle-Thomas KA, Card D, Soorya LV, Wang AT, Fan J, Anagnostou E. Metabolic mapping of deep brain structures and associations with symptomatology in autism spectrum disorders. Res Autism Spectr Disord (2014) 8(1):44-51. doi:10.1016/j.rasd.2013.10.003
25. Harada M, Taki MM, Nose A, Kubo H, Mori K, Nishitani H, et al. Non-invasive evaluation of the GABAergic/glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 tesla instrument. J Autism Dev Disord (2011) 41(4):447-54. doi:10.1007/s10803-010-1065-0
26. Kubas B, Kulak W, Sobaniec W, Tarasow E, Lebkowska U, Walecki J. Metabolite alterations in autistic children: a 1H MR spectroscopy study. Adv Med Sci (2012) 57(1):152-6. doi:10.2478/v10039-012-0014-x
27. O'Roak BJ, Vives L, Girirajan S, Karakoc E, Krumm N, Coe BP, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature (2012) 485(7397):246-50. doi:10.1038/nature10989
28. Yoo HJ, Cho IH, Park M, Yang SY, Kim SA. Family based association of GRIN2A and GRIN2B with Korean autism spectrum disorders. Neurosci Lett (2012) 512(2):89-93. doi:10.1016/j.neulet.2012.01.061
29. Barnby G, Abbott A, Sykes N, Morris A, Weeks DE, Mott R, et al. Candidate-gene screening and association analysis at the autism-susceptibility locus on chromosome 16p: evidence of association at GRIN2A and ABAT. Am J Hum Genet (2005) 76(6):950-66. doi:10.1086/430454
30. Tarabeux J, Kebir O, Gauthier J, Hamdan FF, Xiong L, Piton A, et al. Rare mutations in N-methyl-d-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. Transl Psychiatry (2011) 1:e55. doi:10.1038/tp.2011.52
31. Ramanathan S, Woodroffe A, Flodman PL, Mays LZ, Hanouni M, Modahl CB, et al. A case of autism with an interstitial deletion on 4q leading to hemizygosity for genes encoding for glutamine and glycine neurotransmitter receptor sub-units (AMPA 2, GLRA3, GLRB) and neuropeptide receptors NPY1R, NPY5R. BMC Med Genet (2004) 5:10. doi:10.1186/1471-2156-5-10
32. Jamain S, Betancur C, Quach H, Philippe A, Fellous M, Giros B, et al. Linkage and association of the glutamate receptor 6 gene with autism. Mol Psychiatry (2002) 7(3):302-10. doi:10.1038/sj.mp.4000979
33. Shuang M, Liu J, Jia MX, Yang JZ, Wu SP, Gong XH, et al. Family-based association study between autism and glutamate receptor 6 gene in Chinese Han trios. Am J Med Genet B Neuropsychiatr Genet (2004) 131B(1):48-50. doi:10.1002/ajmg.b.30025
34. Hong CJ, Liou YJ, Liao DL, Hou SJ, Yen FC, Tsai SJ. Association study of polymorphisms in the mitochondrial aspartate/glutamate carrier SLC25A12 (aralar) gene with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2007) 31(7):1510-3. doi:10.1016/j.pnpbp.2007.07.010
35. Ramoz N, Reichert JG, Smith CJ, Silverman JM, Bespalova IN, Davis KL, et al. Linkage and association of the mitochondrial aspartate/glutamate carrier SLC25A12 gene with autism. Am J Psychiatry (2004) 161(4):662-9. doi:10.1176/appi.ajp.161.4.662
36. Segurado R, Conroy J, Meally E, Fitzgerald M, Gill M, Gallagher L. Confirmation of association between autism and the mitochondrial aspartate/glutamate carrier SLC25A12 gene on chromosome 2q31. Am J Psychiatry (2005) 162(11):2182-4. doi:10.1176/appi.ajp.162.11.2182
37. Phelan K, McDermid HE. The 22q13.3 Deletion Syndrome (Phelan-McDermid Syndrome). Mol Syndromol (2012) 2(3-5):186-201
38. D'Antoni S, Spatuzza M, Bonaccorso CM, Musumeci SA, Ciranna L, Nicoletti F, et al. Dysregulation of group-I metabotropic glutamate (mGlu) receptor mediated signalling in disorders associated with Intellectual Disability and Autism. Neurosci Biobehav Rev (2014). doi:10.1016/j.neubiorev.2014.02.003
39. Purcell AE, Jeon OH, Zimmerman AW, Blue ME, Pevsner J. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology (2001) 57(9):1618-28. doi:10.1212/WNL.57.9.1618
40. Fatemi SH, Folsom TD, Kneeland RE, Liesch SB. Metabotropic glutamate receptor 5 upregulation in children with autism is associated with underexpression of both Fragile X mental retardation protein and GABAA receptor beta 3 in adults with autism. Anat Rec (Hoboken) (2011) 294(10):1635-45. doi:10.1002/ar.21299
41. Fatemi SH, Folsom TD. Dysregulation of fragile x mental retardation protein and metabotropic glutamate receptor 5 in superior frontal cortex of individuals with autism: a postmortem brain study. Mol Autism (2011) 2:6. doi:10.1186/2040-2392-2-6
42. Shimmura C, Suzuki K, Iwata Y, Tsuchiya KJ, Ohno K, Matsuzaki H, et al. Enzymes in the glutamate-glutamine cycle in the anterior cingulate cortex in postmortem brain of subjects with autism. Mol Autism (2013) 4(1):6. doi:10.1186/2040-2392-4-6
43. Lepagnol-Bestel AM, Maussion G, Boda B, Cardona A, Iwayama Y, Delezoide AL, et al. SLC25A12 expression is associated with neurite outgrowth and is upregulated in the prefrontal cortex of autistic subjects. Mol Psychiatry (2008) 13(4):385-97. doi:10.1038/sj.mp.4002120
44. Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol (2009) 29(1):51-5. doi:10.1097/JCP.0b013e318192e9a4
45. Grant JE, Odlaug BL, Mooney M, O'Brien R, Kim SW. Open-label pilot study of memantine in the treatment of compulsive buying. Ann Clin Psychiatry (2012) 24(2):119-26
46. Pasquini M, Biondi M. Memantine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2006) 30(6):1173-5. doi:10.1016/j.pnpbp.2006.04.013
47. Feusner JD, Kerwin L, Saxena S, Bystritsky A. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull (2009) 42(1):81-93
48. Grant JE, Chamberlain SR, Odlaug BL, Potenza MN, Kim SW. Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology (Berl) (2010) 212(4):603-12. doi:10.1007/s00213-010-1994-5
49. Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol (2010) 30(1):34-9. doi:10.1097/JCP.0b013e3181c856de
50. Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res (2013) 47(2):175-80. doi:10.1016/j.jpsychires.2012.09.015
51. Haghighi M, Jahangard L, Mohammad-Beigi H, Bajoghli H, Hafezian H, Rahimi A, et al. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl) (2013) 228(4):633-40. doi:10.1007/s00213-013-3067-z
52. Rosi S, Vazdarjanova A, Ramirez-Amaya V, Worley PF, Barnes CA, Wenk GL. Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat. Neuroscience (2006) 142(4):1303-15. doi:10.1016/j.neuroscience.2006.08.017
53. Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, et al. The Oxford 2011 Levels of Evidence: Oxford Centre for Evidence-Based Medicine. (2011). Available from: http://www.cebm.net/index.aspx?o=5653
54. Hardan AY, Handen BL. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol (2002) 12(3):237-41. doi:10.1089/104454602760386923
55. Doyle RL, Frazier J, Spencer TJ, Geller D, Biederman J, Wilens T. Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series. J Atten Disord (2006) 9(3):543-9. doi:10.1177/1087054705284091
56. Buckley AW, Sassower K, Rodriguez AJ, Jennison K, Wingert K, Buckley J, et al. An open label trial of donepezil for enhancement of rapid eye movement sleep in young children with autism spectrum disorders. J Child Adolesc Psychopharmacol (2011) 21(4):353-7. doi:10.1089/cap.2010.0121
57. Srivastava RK, Agarwal M, Pundhir A. Role of donepezil in autism: its conduciveness in psychopharmacotherapy. Case Rep Psychiatry (2011) 2011:563204. doi:10.1155/2011/563204
58. Hertzman M. Galantamine in the treatment of adult autism: a report of three clinical cases. Int J Psychiatry Med (2003) 33(4):395-8. doi:10.2190/JE5Q-1NFT-FL40-7PMW
59. Chez MG, Buchanan TM, Becker M, Kessler J, Aimonovitch MC, Mrazek SR. Donepezil hydrochloride: a double-blind study in autistic children. J Pediatr Neurol (2003) 1(2):83-8
60. Handen BL, Johnson CR, McAuliffe-Bellin S, Murray PJ, Hardan AY. Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures. J Child Adolesc Psychopharmacol (2011) 21(1):43-50. doi:10.1089/cap.2010.0024
61. Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol (2006) 16(5):621-9. doi:10.1089/cap.2006.16.621
62. Niederhofer H, Staffen W, Mair A. Galantamine may be effective in treating autistic disorder. BMJ (2002) 325(7377):1422. doi:10.1136/bmj.325.7377.1422/a
63. Chez MG, Aimonovitch M, Buchanan T, Mrazek S, Tremb RJ. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol (2004) 19(3):165-9
64. Niederhofer H. Treating autism pharmacologically: also tacrine might improve symptomatology in some cases. J Child Neurol (2007) 22(8):1054. doi:10.1177/0883073807305857
65. Chez M, Hung PC, Chin K, Memon S, Kirschner S. Memantine experience in children and adolescents with autistic spectrum disorders. Ann Neurol (2004) 56(8 Suppl):109. doi:10.1002/ana.20263
66. Erickson CA, Chambers JE. Memantine for disruptive behavior in autistic disorder. J Clin Psychiatry (2006) 67(6):1000. doi:10.4088/JCP.v67n0619h
67. Chez MG, Burton Q, Dowling T, Chang M, Khanna P, Kramer C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol (2007) 22(5):574-9. doi:10.1177/0883073807302611
68. Erickson CA, Posey DJ, Stigler KA, Mullett J, Katschke AR, McDougle CJ. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl) (2007) 191(1):141-7. doi:10.1007/s00213-006-0518-9
69. Niederhofer H. Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism. J Clin Psychopharmacol (2007) 27(3):317-8. doi:10.1097/01.jcp.0000270082.30500.69
70. Erickson CA, Mullett JE, McDougle CJ. Open-label memantine in fragile X syndrome. J Autism Dev Disord (2009) 39(12):1629-35. doi:10.1007/s10803-009-0807-3
71. Bernhardt EB, Walsh KH, Posey DJ, McDougle CJ. Memantine for comorbid obsessive-compulsive disorder and Asperger disorder suggests a link in glutamatergic dysregulation. J Clin Psychopharmacol (2011) 31(5):673-5. doi:10.1097/JCP.0b013e31822c92d4
72. Alaghband-Rad J, Nikvarz N, Tehrani-Doost M, Ghaeli P. Memantine-induced speech problems in two patients with autistic disorder. Daru (2013) 21(1):54. doi:10.1186/2008-2231-21-54
73. Ghaleiha A, Asadabadi M, Mohammadi MR, Shahei M, Tabrizi M, Hajiaghaee R, et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol (2013) 16(4):783-9. doi:10.1017/S1461145712000880